Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifampin/Pyrazinamide vs Isoniazid for TB Prevention in HIV
NCT00000638Phase 3Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of rifampicin and pyrazinamide in Tuberculosis (TB) (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Confirmed culture-positive tuberculosis at 3 years. Status: completed.
02
Drugs
rifampicinpyrazinamide
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT00000638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00000638.